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Lung cancer is the largest contributor to mortality from cancer. The National Lung
Screening Trial (NLST) showed that screening with low-dose helical computed tomography (CT) rather than with chest radiography reduced mortality from lung
cancer. We describe the screening, diagnosis, and limited treatment results from
the initial round of screening in the NLST to inform and improve lung-cancer–
screening programs.
Methods

At 33 U.S. centers, from August 2002 through April 2004, we enrolled asymptomatic participants, 55 to 74 years of age, with a history of at least 30 pack-years of
smoking. The participants were randomly assigned to undergo annual screening,
with the use of either low-dose CT or chest radiography, for 3 years. Nodules or
other suspicious findings were classified as positive results. This article reports
findings from the initial screening examination.
Results

A total of 53,439 eligible participants were randomly assigned to a study group
(26,715 to low-dose CT and 26,724 to chest radiography); 26,309 participants
(98.5%) and 26,035 (97.4%), respectively, underwent screening. A total of 7191 participants (27.3%) in the low-dose CT group and 2387 (9.2%) in the radiography
group had a positive screening result; in the respective groups, 6369 participants
(90.4%) and 2176 (92.7%) had at least one follow-up diagnostic procedure, including imaging in 5717 (81.1%) and 2010 (85.6%) and surgery in 297 (4.2%) and 121
(5.2%). Lung cancer was diagnosed in 292 participants (1.1%) in the low-dose CT
group versus 190 (0.7%) in the radiography group (stage 1 in 158 vs. 70 participants
and stage IIB to IV in 120 vs. 112). Sensitivity and specificity were 93.8% and 73.4%
for low-dose CT and 73.5% and 91.3% for chest radiography, respectively.
Conclusions

The NLST initial screening results are consistent with the existing literature on
screening by means of low-dose CT and chest radiography, suggesting that a reduction in mortality from lung cancer is achievable at U.S. screening centers that have
staff experienced in chest CT. (Funded by the National Cancer Institute; NLST
ClinicalTrials.gov number, NCT00047385.)
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L

ung cancer is the largest single
cause of deaths from cancer in the world1-3
and is expected to account for more than
160,000 deaths in the United States during 2013.4
Most patients with lung cancer have smoked
cigarettes.5 Of 94 million U.S. smokers, half are
former smokers whose risk remains elevated decades after cessation.6
In the National Lung Screening Trial (NLST)
of screening for lung cancer in older persons who
were heavy smokers,7 mortality from lung cancer was lower with the use of 3 years of annual
screening with low-dose helical computed tomography (CT) than with the use of chest radiography.8 In addition, the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)9
showed that among approximately 30,000 participants with baseline characteristics that were
similar to those of the NLST participants, mortality from lung cancer did not differ significantly between participants undergoing screening by means of chest radiography and those
receiving usual care,10 confirming the results of
previous randomized trials of screening with the
use of chest radiography.11-13
The NLST, a joint effort of the Lung Screening Study (LSS) and the American College of Radiology Imaging Network (ACRIN), both funded
by the National Cancer Institute (NCI), began
randomly assigning participants in August 2002
to annual screening for 3 years with the use of
either low-dose CT or chest radiography. Details
of the study design7 and the rationale for choosing chest radiography as the control procedure14
have been published previously. A better understanding of the screening process, including the
frequency and management of positive screening
results, can inform the implementation of lungcancer screening programs as well as efforts to
improve them. Here, we describe the screening,
diagnosis, and limited treatment results from
the initial round of screening in the NLST.

Me thods
Study Participants and Study Conduct

At 33 screening centers, we recruited asymptomatic men and women, 55 to 74 years of age, who
had a history of at least 30 pack-years of cigarette
smoking and who were either current smokers or
had been smokers within the previous 15 years.
Participants were randomly assigned to undergo
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annual screening for 3 years with the use of either low-dose CT or chest radiography. The study
was approved by the institutional review board at
each study center, and all participants provided
written informed consent before undergoing randomization. Details of recruitment and randomization methods have been published previously.7
Screening Equipment and Procedures

Low-dose CT was performed on multidetector
helical CT scanners of four or more channels.
Single-view posteroanterior chest radiographs
were obtained with the use of conventional film
or digital radiographic systems. Technical standards and acquisition variables for both low-dose
CT and chest radiographic screening have been
published previously.7,15-17
Image Interpretation

Results were recorded on forms developed for
the study. The screening image was classified as
diagnostic, limited but diagnostic, or nondiagnostic, with the reasons documented.
For low-dose CT, all noncalcified nodules with
long-axis diameters of 4 mm or greater in the
axial plane were considered to be positive for
potential lung cancer. For all positive nodules,
the anatomical location (lobe), longest axial, perpendicular diameters, margin characteristics, attenuation, and representative slice number were
recorded.
For chest radiography, the results were read
on original film or digital image. All noncalcified nodules and masses were considered to be
potentially positive for lung cancer, and for all
positive nodules, the anatomical location, longest
perpendicular diameters, and margin characteristics were recorded.
The interpreting radiologist judged whether
the screening results were positive on the basis
of findings such as noncalcified hilar or mediastinal adenopathy, atelectasis, and pleural disease. Available historical images were reviewed,
and all results and recommendations were recorded. Screening results were classified as positive, negative with clinically significant abnormalities, negative with minor abnormalities, or
negative with no abnormality. Participants without diagnostic results were considered to be
unscreened. Although the NLST had guidelines
for the follow-up of positive screening results,
radiologists could make diagnostic recommennejm.org
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dations as they saw fit. Screening results were mentary Appendix, available with the full text of
reported to the participant and the participant’s this article at NEJM.org). Confidence intervals
designated health care provider, by mail, within were calculated by means of bootstrapping.19
4 weeks.

R e sult s

Follow-up of Study Participants

All participants were mailed annual questionnaires (for the LSS participants) or semiannual
questionnaires (for the ACRIN participants) ascertaining vital status and interim cancer diagnoses. Among participants with positive screening results or with a diagnosis of lung cancer, all
related diagnostic procedures, complications (not
reported here), and results were abstracted by
certified medical-record abstractors.
For cases of diagnosed lung cancer, the histologic type and grade, tumor stage,18 and initial
treatment were documented. To augment the
ascertainment of deaths from questionnaires, the
National Death Index was also searched through
December 31, 2007. Determination of the cause
of death led to the discovery of some previously
unreported cases of lung cancer, which were
also abstracted.
Here, we describe the results of the first
round of screening and diagnostic evaluations
that were initiated on the basis of positive findings at the screening visit, as well as all cancers
diagnosed and treatments initiated at any time
after randomization until the second screening,
if applicable, or until 1 year after the first screening. A diagnostic evaluation consisted of a series of diagnostic procedures with no more than
12 months between consecutive procedures, including the first screening.
Statistical Analysis

We compared the two screening groups with respect to adherence of the participants to the testing protocol, image quality, types of diagnostic
procedures, and results (positive or negative
screening result, ultimate diagnosis, and initial
treatment information). The results were stratified according to group and, in some cases, age,
sex, race, educational level, and smoking history.
All tabulations were performed with the use of
SAS/STAT software, version 9.1 of the SAS System for Unix or version 9.2 for PC (SAS Institute).
Each screening result was judged to be positive or negative, and a strict algorithm was used
to ascertain whether lung cancer was present at
the time of screening (see details in the Supple1982
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Recruitment and Randomization

From August 2002 through April 2004, a total of
53,454 participants were enrolled at 33 sites
across the United States; 26,722 were randomly
assigned to low-dose CT and 26,732 to chest radiography. Figure 1 shows the follow-up of participants during the trial.20 A total of 8 participants had lung cancer and 7 died before the first
scheduled screening. Of the remaining 53,439
participants, 26,715 were in the low-dose CT
group and 26,724 were in the radiography group.
Screening

The first scheduled screening examination was
performed in 98.0% of the participants (52,344
of 53,439) — specifically, in 98.5% of the participants in the low-dose CT group (26,309 of 26,715)
and in 97.4% of those in the chest radiography
group (26,035 of 26,724) (Table 1). Compliance
did not differ significantly according to sex, age,
race or ethnic group, smoking status, or educational level (Table 1, and Table 1 in the Supplementary Appendix). Four participants undergoing low-dose CT and 13 participants undergoing
chest radiography had nondiagnostic results,
none of whom received a diagnosis of lung cancer during the follow-up period. The proportion
of participants with positive screening results
was higher in the low-dose CT group (7191 of
26,309 participants [27.3%]) than in the radiography group (2387 of 26,035 [9.2%]). Rates of
positivity increased slightly with older age and a
larger number of pack-years of smoking in both
screening groups.
The proportion of all screened participants
who had negative screening results but potentially clinically significant, noncancerous abnormalities was higher in the low-dose CT group
(2695 of 26,309 [10.2%]) than in the radiography
group (785 of 26,035 [3.0%]).
Screening Accuracy

During the baseline follow-up period, lung cancer was diagnosed in 292 of the 26,309 participants (1.1%) who underwent low-dose CT screening versus 190 of the 26,035 participants (0.7%)
nejm.org
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19,043 Did not have lung
cancer
18 Had lung cancer
57 Had unknown
status

19,118 Had negative result

2387 Had positive result

2243 Did not have lung
cancer
136 Had lung cancer
8 Had unknown
status

6911 Did not have lung
cancer
270 Had lung cancer
10 Had unknown
status

23,547 Did not have lung
cancer
49 Had lung cancer
52 Had unknown
status

23,648 Had negative result

5 Had lung cancer

689 Were not screened
596 Declined to participate
44 Underwent incorrect
screening procedure
29 Withdrew from study
13 Had inadequate
results
7 Did not submit
screening form

8 Were excluded
3 Had lung cancer
5 Died

26,035 Were screened with radiography

26,724 Were eligible for radiography

7191 Had positive result

26,309 Were screened with low-dose CT

26,715 Were eligible for low-dose CT

26,732 Were assigned to radiography

Figure 1. Enrollment and Follow-up of the Study Participants after the Initial Screening.
A total of 490 lung cancers were diagnosed: 406 in participants with positive screening results (270 in the low-dose computed tomography [CT] group and 136 in the radiography
group), 67 in participants with negative results (18 and 49, respectively), and 9 in participants who missed the screening (4 and 5, respectively), as well as an additional 8 cancers in
participants who were ineligible for the initial screening but received a diagnosis of lung cancer during the screening period (5 and 3, respectively). If an inadequate examination
was performed (e.g., because of its quality, the image was not interpretable) and no rescreening took place, the participant was considered not to have been screened.

4 Had lung cancer

406 Were not screened
357 Declined to participate
29 Underwent incorrect
screening procedure
11 Withdrew from study
4 Had inadequate
results
5 Did not submit
screening form

7 Were excluded
5 Had lung cancer
2 Died

26,722 Were assigned to low-dose CT

53,454 Participants underwent randomization
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Table 1. Baseline Characteristics of the Study Participants, According to Study Group.*
Characteristic

Low-Dose CT
Randomized

Screened

Chest Radiography
Positive
Result

Randomized

Screened

Positive
Result

number (percent)
All participants

26,715

26,309 (98.5) 7191 (27.3)

26,724

26,035 (97.4)

2387 (9.2)

Sex
Male

15,765

15,539 (98.6) 4194 (27.0)

15,758

15,400 (97.7)

1504 (9.8)

Female

10,950

10,770 (98.4) 2997 (27.8)

10,966

10,635 (97.0)

883 (8.3)

1 (50.0)

4

4 (100)

Age
≤54 yr

2

2 (100)

0

55–59 yr

11,436

11,245 (98.3) 2730 (24.3)

11,417

11,103 (97.2)

870 (7.8)

60–64 yr

8,168

8,059 (98.7) 2217 (27.5)

8,196

7,975 (97.3)

747 (9.4)

65–69 yr

4,755

4,689 (98.6) 1456 (31.1)

4,760

4,661 (97.9)

480 (10.3)

70–74 yr

2,353

2,313 (98.3)

2,344

2,289 (97.7)

289 (12.6)

1

1 (100)

0

3

3 (100)

1 (33.3)

4

4 (100)

0

11

11 (100)

≥75 yr

787 (34.0)

Smoking status†
Former smoker
0 to <30 pack-yr

0

30 to <35 pack-yr

1,824

1,798 (98.6)

433 (24.1)

1,905

1,859 (97.6)

140 (7.5)

35 to <40 pack-yr

2,043

2,010 (98.4)

518 (25.8)

1,966

1,926 (98.0)

172 (8.9)

40 to <45 pack-yr

1,813

1,802 (99.4)

491 (27.2)

1,761

1,728 (98.1)

162 (9.4)

45 to <50 pack-yr

1,423

1,407 (98.9)

394 (28.0)

1,354

1,325 (97.9)

122 (9.2)

≥50 pack-yr

6,749

6,645 (98.5) 1791 (27.0)

6,832

6,666 (97.6)

608 (9.1)

13,856

13,666 (98.6) 3627 (26.5)

13,829

13,515 (97.7)

1204 (8.9)

Total
Current smoker
0 to <30 pack-yr
30 to <35 pack-yr

2

2 (100)

1,099

1,081 (98.4)

0
251 (23.2)

4

4 (100)

1,152

1,117 (97.0)

1 (25.0)
93 (8.3)

35 to <40 pack-yr

1,859

1,834 (98.7)

453 (24.7)

1,869

1,820 (97.4)

131 (7.2)

40 to <45 pack-yr

2,394

2,353 (98.3)

646 (27.5)

2,304

2,232 (96.9)

200 (9.0)

45 to <50 pack-yr

1,549

1,523 (98.3)

444 (29.2)

1,585

1,534 (96.8)

172 (11.2)

≥50 pack-yr

5,956

5,850 (98.2) 1770 (30.3)

5,981

5,813 (97.2)

586 (10.1)

12,859

12,643 (98.3) 3564 (28.2)

12,895

12,520 (97.1)

Total

1183 (9.4)

* Participants 54 years of age or younger and those 75 years of age or older at enrollment were ineligible for the study, as
were those with less than 30 pack-years of smoking, but data for them were included in the intention-to-treat analysis.
† Former smokers were participants who reported having quit tobacco use; current smokers were participants who reported that they were currently using tobacco.

who underwent radiographic screening (Fig. 1);
2 cases of lung cancer in each group were first
reported in the National Death Index. In the lowdose CT group, 270 (92.5%) of the participants
with lung cancer had a positive screening result
(a true positive result), 18 (6.2%) had a negative
screening result (a false negative result), and 4
(1.4%) missed the screening visit. In the radiog1984
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raphy group, 136 (71.6%) of the participants with
lung cancer had a positive screening result (a true
positive result), 49 (25.8%) had a negative screening result (a false negative result), and 5 (2.6%)
missed the screening visit. The sensitivity and
specificity were 93.8% (270 of 288; 95% confidence interval [CI], 90.6 to 96.3) and 73.4%
(19,043 of 25,954; 95% CI, 72.8 to 73.9), respecnejm.org
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tively, for low-dose CT and 73.5% (136 of 185;
95% CI, 67.2 to 79.8) and 91.3% (23,547 of 25,790;
95% CI, 91.0 to 91.6), respectively, for chest radiography.
In the low-dose CT group, the positive predictive value for any positive finding that led to a
biopsy procedure was 52.9% (265 of 501; 95%
CI, 48.4 to 57.4), but the positive predictive value
for positive screening results overall was only
3.8% (270 of 7181; 95% CI, 3.3 to 4.2) (Table 2).
The positive predictive value for pulmonary nodules 4 mm or more in the longest diameter was
3.8% (267 of 7010; 95% CI, 3.4 to 4.3); the value
increased from 0.5% to 41.3% as the diameter of
the nodule increased from 4 to 6 mm to more
than 30 mm. The positive predictive value for
noncalcified hilar or mediastinal adenopathy
was 18.5% (51 of 276; 95% CI, 14.1 to 23.4).
Overall, with low-dose CT, the negative predictive value was 99.9% (19,043 of 19,061; 95% CI,
99.86 to 99.94).
In the radiography group, the positive predictive value was 70.2% (132 of 188; 95% CI, 64.0
to 76.8) for a positive screening result that led to
a biopsy procedure but only 5.7% (136 of 2379;
95% CI, 4.8 to 6.6) for positive screening results
overall (Table 2). The positive predictive value for
pulmonary nodules was 5.8% (123 of 2105; 95%
CI, 4.9 to 6.9); the value increased from 1.0% to
39.3% as the diameter of the nodule increased
from 4 to 6 mm to more than 30 mm. The
positive predictive value for noncalcified hilar or
mediastinal adenopathy was 9.3% (8 of 86; 95%
CI, 3.8 to 15.8). Overall the negative predictive
value was 99.8% (23,547 of 23,596; 95% CI, 99.7
to 99.8).
The positive predictive values for atelectasis
and consolidation could not be reliably estimated because, unlike pulmonary nodules 4 mm or
greater in the longest diameter, these findings
were not always considered to be positive and,
even when reported on a positive screening result, they often coexisted with pulmonary nodules and so may not have determined a positive
screening test.
Diagnostic Follow-up Procedures

Of the 9578 participants with positive screening
results, 9397 (98.1%) had completely documented diagnostic follow-up. At least one diagnostic
procedure was performed in 6369 of 7049 participants (90.4%) in the low-dose CT group and
n engl j med 368;21

in 2176 of 2438 participants (92.7%) in the radiography group (Table 3). A total of 5717 participants (81.1%) and 2010 (85.6%) participants in
the two groups, respectively, underwent at least
one follow-up imaging procedure, with chest CT
performed in 5153 (73.1%) and 1546 (65.8%) and
18F-fluorodeoxyglucose–positron-emission tomography (FDG-PET) performed in 728 (10.3%) and
179 (7.6%); 155 (2.2%) and 83 (3.5%) underwent
at least one percutaneous cytologic or biopsy procedure; 306 (4.3%) and 107 (4.6%) underwent at
least one bronchoscopy (with or without transbronchial biopsy); and 297 (4.2%) and 121 (5.2%)
underwent at least one diagnostic surgical procedure. In the low-dose CT group, thoracoscopy
was performed in 44 participants with true positive results and in 38 participants with false
positive results. In the radiography group, thoracoscopy was performed in 14 participants and
8 participants with true positive results and false
positive results, respectively.
Because some of the imaging procedures were
performed more than once in the same participant, a comparison of the total numbers of procedures in the two groups may best reflect the
diagnostic burden. In the low-dose CT group, a
total of 10,313 imaging procedures were performed, including 7288 chest CT examinations,
as compared with 3657 imaging procedures in
the radiography group, including 2158 chest CT
examinations.
Procedure records were collected routinely
only for participants with a positive screening
result. However, participants with a negative
screening result may also have undergone diagnostic procedures prompted by the screening result; thus, the data shown in Table 3 underrepresent the total number of procedures prompted
by the screening examination.
Stage, Histologic Features, and Treatment
of Lung Cancer

There were 292 cases of diagnosed lung cancer in
the low-dose CT group and 190 in the radiography group, with the difference nearly completely
accounted for by the higher incidence of stage IA
cancer in the low-dose CT group (132 cases, vs.
46 in the radiography group). Table 4 shows the
characteristics of the diagnosed lung cancers.
There was no significant difference in the total
number of lung cancers in stages IIB through IV
between the low-dose CT group and the radiognejm.org
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267 (98.9)

With noncalcified nodule or mass

<4 mm
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45 (16.7)

>30 mm

51 (18.9)
7 (2.6)
16 (5.9)

Noncalcified hilar or mediastinal
adenopathy or mass

Consolidation‡

Pleural thickening or effusion

439 (6.4)

80 (1.2)

225 (3.3)

69 (1.0)

1 (10.0)

0

1 (10.0)

0

0

0

0

0

456 (6.3)

87 (1.2)

277 (3.9)

72 (1.0)

21 (0.3)

109 (1.5)

195 (2.7)

932 (13.0)

3.8

3.5

8.0

18.5

4.2

0.0

41.3

29.7

11.9

1.7

0.5

3.8

0.0

3.8

52.9

1.9–5.3

2.6–14.4

14.1–23.4

0.0–9.0

0.0–0.0

32.1–51.0

23.7–36.4

9.8–13.9

1.1–2.2

0.3–0.7

3.4–4.3

0.0–0.0

3.3–4.2

48.4–57.4

3.3–4.2

percent

PPV
Range

10 (7.4)

3 (2.2)

8 (5.9)

4 (2.9)

7 (5.1)

33 (24.3)

27 (19.9)

38 (27.9)

12 (8.8)

5 (3.7)

115 (84.6)

1 (0.7)

123 (90.4)

132 (97.1)

136

yes

161 (7.2)

41 (1.8)

78 (3.5)

24 (1.1)

135 (6.0)

51 (2.3)

92 (4.1)

481 (21.4)

692 (30.9)

491 (21.9)

1807 (80.6)

40 (1.8)

1982 (88.4)

56 (2.5)

2243

no

1 (12.5)

1 (12.5)

0

0

0

0

0

2 (25.0)

2 (25.0)

2 (25.0)

6 (75.0)

1 (12.5)

7 (87.5)

0

8

unknown

Confirmed Lung Cancer

172 (7.2)

45 (1.9)

86 (3.6)

28 (1.2)

142 (5.9)

84 (3.5)

119 (5.0)

521 (21.8)

706 (29.6)

498 (20.9)

1928 (80.8)

42 (1.8)

2112 (88.5)

188 (7.9)

2387

Total

4.8–6.6

percent

PPV
Range

5.1–9.7

0.8–2.9

0.2–2.0

4.9–7.1

0.0–7.9

4.9–6.9

5.8

6.8

9.3

14.3

4.9

2.5–9.4

0.0–14.4

3.8–15.8

3.4–29.5

1.8–8.7

39.3 28.6–50.6

22.7 15.2–30.4

7.3

1.7

1.0

6.0

2.4

5.8

70.2 64.0–76.8

5.7

PPV

* Data are number (percent) unless otherwise indicated. The patients with confirmed lung cancer do not include 76 participants in whom lung cancer was diagnosed during the initialscreening year: 9 who did not undergo the initial screening and 67 who had negative screening results. The positive predictive value (PPV) is defined as the proportion of patients with
confirmed lung cancer among those with a positive result on screening whose lung-cancer status was known.
† Nodule size refers to the diameter of the largest nodule recorded on the screening examination.
‡ Because these conditions were not always considered positive, the PPV could not be reliably estimated.

3 (1.1)

Atelectasis, segmental or more
extensive‡

21 (0.3)

64 (0.9)

137 (2.0)

821 (11.9)

2115 (29.4)

3668 (51.0)

7019 (97.6)

1 (<1)

7041 (97.9)

501 (7.0)

7191

PPV

Chest Radiography

of

Other findings

0

58 (21.5)

21–30 mm

1 (10.0)

8 (80.0)

9 (90.0)

0

9 (90.0)

0

10

unknown

Total

Low-Dose CT

n e w e ng l a n d j o u r na l

Unknown

111 (41.1)

11–20 mm

2079 (30.1)

3642 (52.7)

18 (6.7)
35 (13.0)

4–6 mm

6743 (97.6)

1 (<1)

6765 (97.9)

236 (3.4)

6911

no

267 (98.9)

7–10 mm

≥4 mm

0

265 (98.1)

Size of nodule or mass†

270

Positive screening

yes

Confirmed Lung Cancer

With subsequent biopsy

Patients

Finding at Initial Screening

Table 2. Frequency and Positive Predictive Value of Positive Screening Results, According to Study Group.*
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Table 3. Diagnostic Follow-up of Positive Screening Results among the 9397 Patients with Data, According to Study
Group and Lung-Cancer Status.*
Follow-up

Low-Dose CT
Confirmed Lung Cancer†
yes
(N = 270)

Chest Radiography
Total
(N = 7049)

no
(N = 6779)

Confirmed Lung Cancer†
yes
(N = 136)

Total
(N = 2348)

no
(N = 2212)

number (percent)
Any diagnostic follow-up

270 (100)

6099 (90.0)

6369 (90.4)

136 (100)

2040 (92.2) 2176 (92.7)

Clinical evaluation

248 (91.9)

4841 (71.4)

5089 (72.2)

117 (86.0)

1297 (58.6) 1414 (60.2)

Imaging studies

1874 (84.7) 2010 (85.6)

258 (95.6)

5459 (80.5)

5717 (81.1)

136 (100)

Chest radiography

112 (41.5)

1172 (17.3)

1284 (18.2)

63 (46.3)

Chest CT

181 (67.0)

4972 (73.3)

5153 (73.1)

131 (96.3)

FDG-PET or FDG-PET and CT

171 (63.3)

557 (8.2)

728 (10.3)

90 (66.2)

89 (4.0)

179 (7.6)

98 (36.3)

57 (0.8)

155 (2.2)

66 (48.5)

17 (0.8)

83 (3.5)

77 (28.5)

43 (0.6)

120 (1.7)

54 (39.7)

13 (0.6)

67 (2.9)

Percutaneous cytologic analysis or
biopsy
Transthoracic
Extrathoracic

804 (36.3)

867 (36.9)

1415 (64.0) 1546 (65.8)

23 (8.5)

16 (0.2)

39 (0.6)

16 (11.8)

4 (0.2)

20 (0.9)

158 (58.5)

148 (2.2)

306 (4.3)

76 (55.9)

31 (1.4)

107 (4.6)

With neither biopsy nor cytologic
analysis

84 (31.1)

42 (0.6)

126 (1.8)

34 (25.0)

11 (0.5)

45 (1.9)

With biopsy or cytologic analysis

86 (31.9)

108 (1.6)

194 (2.8)

51 (37.5)

23 (1.0)

74 (3.2)

207 (76.7)

90 (1.3)

297 (4.2)

96 (70.6)

25 (1.1)

121 (5.2)

48 (17.8)

12 (0.2)

60 (0.9)

22 (16.2)

Thoracoscopy

44 (16.3)

38 (0.6)

82 (1.2)

Thoracotomy

156 (57.8)

41 (0.6)

197 (2.8)

Other procedure

46 (17.0)

122 (1.8)

168 (2.4)

Bronchoscopy

Surgical procedure
Mediastinoscopy or mediastinotomy

0

22 (0.9)

14 (10.3)

8 (0.4)

22 (0.9)

78 (57.4)

18 (0.8)

96 (4.1)

17 (12.5)

38 (1.7)

55 (2.3)

* Numbers refer to the number of participants with a positive screening result who underwent any diagnostic procedure
at least once. Not included are participants with a positive screening result for whom information on diagnostic procedures was incomplete (142 in the low-dose CT group and 39 in the radiography group). Diagnostic procedures were defined as follows: clinical evaluation (evaluation during an outpatient visit — physical examination, pulmonary-function
testing, sputum cytologic assessment, or comparison of screening results with historical images), chest CT (diagnostic,
low-dose, or limited-anatomy chest CT, with or without concurrent CT examination of the abdomen, pelvis, head and
neck, or brain), fluorodeoxyglucose–positron-emission tomography (FDG-PET) CT (F-18 or fusion), extrathoracic percutaneous cytology or biopsy (extrathoracic lymph-node biopsy or percutaneous biopsy of liver, adrenal, or other extrathoracic tissue), thoracoscopy (with or without biopsy), or other procedures (other cytologic or biopsy procedures, procedures coded as “unknown,” and procedures other than those listed by name on data-collection forms).
† The participants with confirmed lung cancer do not include the 8 participants who were ineligible for the initial screening
because of a prior lung-cancer diagnosis and 76 participants who received a diagnosis of lung cancer during the initialscreening year (9 who did not undergo screening and 67 with a negative screening result). “No” denotes lung cancer
that was not confirmed because of a negative diagnostic result or an unknown reference standard.

raphy group (120 vs. 112). There were many more
bronchioloalveolar carcinomas and adenocarcinomas in the low-dose CT group than in the radiography group (38 vs. 8 and 123 vs. 71, respectively), but the frequencies of other histologic
features were similar in the two groups. More
patients with lung cancer were treated with some
combination of surgery, chemotherapy, and ran engl j med 368;21

diotherapy in the low-dose CT group than in the
radiography group (277 vs. 181), but stage IA
cancers that were treated only with surgery accounted for most of the difference (117 such cancers in the low-dose CT group vs. 40 in the radiography group) (Table 2 in the Supplementary
Appendix). Only 10 patients in the low-dose CT
group and 6 patients in the radiography group
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1/18 (5.6)

7/266 (2.6)

n engl j med 368;21

0

4/270 (1.5)

nejm.org

2/268 (0.7)
2/270 (0.7)

Unknown

4/18 (22.2)
0

0

0

0

1/4 (25.0)

1/4 (25.0)

0

1/4 (25.0)

1/4 (25.0)

0

0

2/292 (0.7)

2/290 (0.7)

20/290 (6.9)

36/290 (12.4)

17/290 (5.9)

54/290 (18.6)

123/290 (42.4)

38/290 (13.1)

4/292 (1.4)

44/288 (15.3)

30/288 (10.4)

34/288 (11.8)

12/288 (4.2)

10/288 (3.5)

26/288 (9.0)

132/288 (45.8)

0

0

15/136 (11.0)

20/136 (14.7)

8/136 (5.9)

32/136 (23.5)

53/136 (39.0)

8/136 (5.9)

3/136 (2.2)

26/133 (19.5)

15/133 (11.3)

19/133 (14.3)

8/133 (6.0)

3/133 (2.3)

22/133 (16.5)

40/133 (30.1)

1/49 (2.0)

1/48 (2.1)

11/48 (22.9)

9/48 (18.8)

5/48 (10.4)

7/48 (14.6)

15/48 (31.2)

0

1/49 (2.0)

18/48 (37.5)

12/48 (25.0)

8/48 (16.7)

2/48 (4.2)

0

2/48 (4.2)

6/48 (12.5)

Negative
(N = 49)

0

0

1/5 (20.0)

1/5 (20.0)

0

0

3/5 (60.0)

0

1/5 (20.0)

2/4 (50.0)

0

2/4 (50.0)

0

0

0

0

None
(N = 5)

1/190 (0.5)

1/189 (0.5)

27/189 (14.3)

30/189 (15.9)

13/189 (6.9)

39/189 (20.6)

71/189 (37.6)

8/189 (4.2)

5/190 (2.6)

46/185 (24.9)

27/185 (14.6)

29/185 (15.7)

10/185 (5.4)

3/185 (1.6)

24/185 (13.0)

46/185 (24.9)

Total
(N = 190)

* Cancer-stage classification is based on the sixth edition of the Cancer Staging Manual of the American Joint Committee on Cancer.21 The denominators for cancer stage and histologic
features were the total number of cancers with a known stage and the total number of cancers with known histologic features, respectively. Negative screening results include findings
that were classified as either minor or clinically significant abnormalities that were not suggestive of lung cancer.
† The 9 lung cancers of unknown stage included 2 carcinoids, 1 occult carcinoma, 2 with stage information that could not be classified, and 4 for which medical records were missing.
‡ The 66 lung cancers in this category included 8 adenosquamous carcinomas, 2 sarcomatoid carcinomas, 5 unclassified carcinomas, and 51 carcinomas coded only as “non–small-cell
carcinoma.”

15/268 (5.6)

Small-cell carcinoma

Carcinoid

1/18 (5.6)

3/18 (16.7)

14/268 (5.2)
34/268 (12.7)

Large-cell carcinoma

2/4 (50.0)
0

Positive
(N = 136)

number/total number (percent)

Total
(N = 292)

of

Non–small-cell carcinoma, other
classification‡

6/18 (33.3)

4/18 (22.2)

0

7/18 (38.9)

1/4 (25.0)

0

1/4 (25.0)

0

0

None
(N = 4)

Chest Radiography

n e w e ng l a n d j o u r na l

47/268 (17.5)

118/268 (44.0)

Adenocarcinoma

Squamous-cell carcinoma

38/268 (14.2)

Bronchioloalveolar carcinoma

Histologic features

Unknown†

3/18 (16.7)

21/266 (7.9)
41/266 (15.4)

IIIB

IV

2/18 (11.1)

11/266 (4.1)
31/266 (11.7)

IIB

IIIA

1/18 (5.6)

2/18 (11.1)

25/266 (9.4)

IB

IIA

Negative
(N = 18)

2/18 (11.1)

Positive
(N = 270)

Low-Dose CT

130/266 (48.9)

IA

Stage

Stage or Finding

Table 4. Stage and Histologic Features of Lung Cancers, According to Study Group and Screening Result.*
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received no treatment at all. However, for each
cancer stage, the relative frequencies of treatment types did not differ significantly between
the two screening groups (Table 1 in the Supplementary Appendix).

Discussion
We report the prevalence of abnormalities in the
NLST population at the onset of screening.8 As
expected, more positive screening results, more
diagnostic procedures, more biopsies and other
invasive procedures, and more lung cancers were
seen in the low-dose CT group than in the radiography group during the first screening round.
In addition, more early-stage lung cancers, but
similar numbers of late-stage cancers, were diagnosed in the low-dose CT group.
Our findings for screening with the use of
low-dose CT are similar to those in previous large
studies of low-dose CT screening (Early Lung
Cancer Action Project [ELCAP],22 International
Early Lung Cancer Action Program [I-ELCAP],23
Mayo,24 Milano,25 Lung Screening Study Feasibility Phase,26 Pittsburgh,27 and NELSON [Current
Controlled Trials number, ISRCTN63545820]28).
The ages and smoking histories of our participants were similar to those of participants in
most of these studies. In addition, the sensitivity
(93.8%), specificity (73.4%), rate of positive
screening results (27.3%), and positive predictive
value (3.8%) of low-dose CT were in the midrange
of the corresponding values in the previous studies, as was the proportion of participants who
underwent biopsy (1.9%).
Two additional findings suggest that screening by means of low-dose CT was well implemented in our study. The compliance rate of
98.5% was much higher than the 85% rate that
was assumed for each screening round in our
sample-size calculation, and only four of the lowdose CT scans were judged to be nondiagnostic.
The high rate of positive screening results
(and the low positive predictive value) with lowdose CT resulted in the performance of many
diagnostic procedures. Nonetheless, the number
of follow-up chest CT scans per positive screening result in the low-dose CT group was modest
— approximately 1 scan per positive screening
result (i.e., 7288 CT scans performed per 7049
participants with a positive result of low-dose
CT scanning). A recent cost-effectiveness analyn engl j med 368;21

sis of lung-cancer screening29 assumed, for the
baseline case, that nodules 4 to 8 mm (presumably in the longest diameter) would be evaluated
by means of serial CT at 3, 6, and 9 months, on
the basis of the protocol for the Mayo study,30
which started in 1999. Subsequent reports have
recommended less frequent follow-up CT, as reflected in our trial, which should improve the
cost-effectiveness of the procedure in the face of
its high rate of positive results.
Some of our findings with respect to the initial low-dose CT screening are not fully consistent with those reported previously. The prevalence of lung cancer (1.1%) is at the low end of
the reported range in prior large studies of participants with similar smoking histories (1.0 to
2.8%) but is close to the rate of 1.0% in the
NELSON trial, the most recent study that is comparable to ours. This low rate may be due to
some combination of the following factors: the
healthy-volunteer effect (volunteers in trials are
healthier than the general population), a younger population in our study than in the most recent studies, the high proportion of former
smokers in our study, and the limitations of
lung-cancer prediction estimates that are based
on pack-years.31 The proportion of all lung cancers classified as stage I (55%) was also low
relative to the range reported in other studies
(54 to 85%), but this may be partly due to exclusion of small-cell cancer in the other studies and
the more frequent use of PET-CT to ascertain the
cancer stage in our study. Adenocarcinoma was
the most common histologic finding in both our
study and previous studies. Bronchioloalveolar
carcinoma occurred about twice as frequently in
our study (with a rate of 13%) than in others,
possibly because of higher spatial resolution of the
screening procedure and more frequent reporting of this type of carcinoma. Bronchioloalveolar
carcinoma is no longer reported in many centers, on the basis of recent recommendations,32
and may soon be only of historical interest.
The results of chest radiography in our study
were also similar to those in the comparable
subgroup of participants in the PLCO radiography group.10 In our radiography group and the
PLCO radiography subgroup, 9.2% and 11.0% of
participants, respectively, had positive screening
results; 0.7% and 0.8% underwent biopsy; and
0.5% and 0.6% had lung cancer detected on
screening; the sensitivity in the respective groups
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was 74% and 77%, the specificity was 91% and
90%, and the positive predictive value was 5.7%
and 5.5%. These similarities suggest that more
important outcomes, including mortality from
lung cancer, should also be similar.
Several limitations of our study deserve discussion. Our participants were similar to the
general population of smokers in the United
States except for a higher proportion of former
smokers and a higher educational level, which
may partly explain the lower prevalence of lung
cancer in our study than in other studies. This
suggests that caution should be used in generalizing other results of the initial round of screening in our study to the U.S. population of
smokers. In addition, because the numbers of
follow-up procedures were counted only in participants with positive screening results, they undoubtedly underestimate the frequency of diagnostic procedures performed because of a screening
result (e.g., procedures performed to investigate
potentially clinically significant abnormalities).
Finally, because mortality was not reduced by
screening with chest radiography among the

of
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PLCO participants who were comparable to our
participants,10 the anticipated comparison of
the results of our first round of low-dose CT
screening with no screening in the ongoing
NELSON trial should be of great interest.
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